Avita Medical Shares Fall on Preliminary Sales Miss

Dow Jones

2025/10/17

By Katherine Hamilton

Shares of Avita Medical shares were lower after the company's preliminary third-quarter revenue came in below analyst expectations.

The stock shed 20% to $4.33 before the market opened Friday. Through the close, shares had lost 58% of their value.

The wound-care company said Thursday it expects sales in the quarter ended Sept. 30 to be $17 million, below the $19.2 million Wall Street was forecasting, according to FactSet.

Avita said it is assessing annual guidance and will provide an update on its view during its scheduled Nov. 6 call. The company in August cut its full-year revenue outlook after second-quarter revenue came in about $4 million below consensus estimates.

The company has been grappling with a delay in provider payment due to a change in the Centers for Medicare and Medicaid Services codes for the use of Avita's wound-treatment product Recell.

Issues with provider reimbursement starting in Janurary have constrained demand, with Recell revenue declining by $5 million across Avita's top 10 hospital accounts in the first half of 2025. The company had estimated in August that demand for Recell declined by about 20% and revenue fell by $10 million in the first half of the fiscal year.

Avita also on Thursday evening said its chief executive, Jim Corbett, would step down. Corbett has served since September 2022 and will be succeeded by board chair Cary Vance in an interim role.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

October 17, 2025 06:28 ET (10:28 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2576036328"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2576036328\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2576036328?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-17 18:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2576036328","market":"sg","top_or_hot":-1,"title":"Avita Medical Shares Fall on Preliminary Sales Miss","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Avita Medical shares were lower after the company's preliminary third-quarter revenue came in below analyst expectations. \n</p>\n<p>\n  The stock shed 20% to $4.33 before the market opened Friday. Through the close, shares had lost 58% of their value. \n</p>\n<p>\n  The wound-care company said Thursday it expects sales in the quarter ended Sept. 30 to be $17 million, below the $19.2 million Wall Street was forecasting, according to FactSet. \n</p>\n<p>\n  Avita said it is assessing annual guidance and will provide an update on its view during its scheduled Nov. 6 call. The company in August cut its full-year revenue outlook after second-quarter revenue came in about $4 million below consensus estimates. \n</p>\n<p>\n  The company has been grappling with a delay in provider payment due to a change in the Centers for Medicare and Medicaid Services codes for the use of Avita's wound-treatment product Recell. \n</p>\n<p>\n  Issues with provider reimbursement starting in Janurary have constrained demand, with Recell revenue declining by $5 million across Avita's top 10 hospital accounts in the first half of 2025. The company had estimated in August that demand for Recell declined by about 20% and revenue fell by $10 million in the first half of the fiscal year. \n</p>\n<p>\n  Avita also on Thursday evening said its chief executive, Jim Corbett, would step down. Corbett has served since September 2022 and will be succeeded by board chair Cary Vance in an interim role. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 17, 2025 06:28 ET (10:28 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Avita Medical Shares Fall on Preliminary Sales Miss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAvita Medical Shares Fall on Preliminary Sales Miss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-10-17 18:28</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Avita Medical shares were lower after the company's preliminary third-quarter revenue came in below analyst expectations. \n</p>\n<p>\n  The stock shed 20% to $4.33 before the market opened Friday. Through the close, shares had lost 58% of their value. \n</p>\n<p>\n  The wound-care company said Thursday it expects sales in the quarter ended Sept. 30 to be $17 million, below the $19.2 million Wall Street was forecasting, according to FactSet. \n</p>\n<p>\n  Avita said it is assessing annual guidance and will provide an update on its view during its scheduled Nov. 6 call. The company in August cut its full-year revenue outlook after second-quarter revenue came in about $4 million below consensus estimates. \n</p>\n<p>\n  The company has been grappling with a delay in provider payment due to a change in the Centers for Medicare and Medicaid Services codes for the use of Avita's wound-treatment product Recell. \n</p>\n<p>\n  Issues with provider reimbursement starting in Janurary have constrained demand, with Recell revenue declining by $5 million across Avita's top 10 hospital accounts in the first half of 2025. The company had estimated in August that demand for Recell declined by about 20% and revenue fell by $10 million in the first half of the fiscal year. \n</p>\n<p>\n  Avita also on Thursday evening said its chief executive, Jim Corbett, would step down. Corbett has served since September 2022 and will be succeeded by board chair Cary Vance in an interim role. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 17, 2025 06:28 ET (10:28 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RCEL","symbol_name":"Avita Medical Ltd.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2576036328","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2576036328","pubTimestamp":1760696880,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Avita Medical shares were lower after the company's preliminary third-quarter revenue came in below analyst expectations.The stock shed 20% to $4.33 before the market opened Friday. Through the close, shares had lost 58% of their value.The wound-care company said Thursday it expects sales in the quarter ended Sept. 30 to be $17 million, below the $19.2 million Wall Street was forecasting, according to FactSet.Avita said it is assessing annual guidance and will provide an update on its view during its scheduled Nov. 6 call. The company in August cut its full-year revenue outlook after second-quarter revenue came in about $4 million below consensus estimates.Issues with provider reimbursement starting in Janurary have constrained demand, with Recell revenue declining by $5 million across Avita's top 10 hospital accounts in the first half of 2025. The company had estimated in August that demand for Recell declined by about 20% and revenue fell by $10 million in the first half of","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RCEL":"Avita Medical Ltd.","BK4139":"生物科技"},"translate_title":"阿维塔医疗股价因初步销售未达标而下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RCEL":0.9},"content_text":"By Katherine Hamilton \n\n\n \n\n\n  Shares of Avita Medical shares were lower after the company's preliminary third-quarter revenue came in below analyst expectations. \n\n\n  The stock shed 20% to $4.33 before the market opened Friday. Through the close, shares had lost 58% of their value. \n\n\n  The wound-care company said Thursday it expects sales in the quarter ended Sept. 30 to be $17 million, below the $19.2 million Wall Street was forecasting, according to FactSet. \n\n\n  Avita said it is assessing annual guidance and will provide an update on its view during its scheduled Nov. 6 call. The company in August cut its full-year revenue outlook after second-quarter revenue came in about $4 million below consensus estimates. \n\n\n  The company has been grappling with a delay in provider payment due to a change in the Centers for Medicare and Medicaid Services codes for the use of Avita's wound-treatment product Recell. \n\n\n  Issues with provider reimbursement starting in Janurary have constrained demand, with Recell revenue declining by $5 million across Avita's top 10 hospital accounts in the first half of 2025. The company had estimated in August that demand for Recell declined by about 20% and revenue fell by $10 million in the first half of the fiscal year. \n\n\n  Avita also on Thursday evening said its chief executive, Jim Corbett, would step down. Corbett has served since September 2022 and will be succeeded by board chair Cary Vance in an interim role. \n\n\n \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 17, 2025 06:28 ET (10:28 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}